JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating for LAVA Therapeutics (NASDAQ:LVTX) and maintained a $6 price target.
August 21, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for LAVA Therapeutics, maintaining a $6 price target, indicating confidence in the company's potential.
The reiteration of a Market Outperform rating and maintenance of a $6 price target by JMP Securities suggests a positive outlook for LAVA Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100